Financial Advocates Investment Management Cuts Stock Holdings in Sanofi (NASDAQ:SNY)

Financial Advocates Investment Management cut its stake in shares of Sanofi (NASDAQ:SNY) by 9.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,709 shares of the company’s stock after selling 618 shares during the period. Financial Advocates Investment Management’s holdings in Sanofi were worth $275,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after acquiring an additional 751 shares in the last quarter. Geode Capital Management LLC boosted its position in Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, GFS Advisors LLC lifted its stake in shares of Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after purchasing an additional 11,655 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNY has been the subject of a number of recent research reports. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

SNY stock opened at $53.35 on Monday. The company has a market capitalization of $135.39 billion, a PE ratio of 21.43, a P/E/G ratio of 0.99 and a beta of 0.57. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average is $49.72 and its two-hundred day moving average is $52.39. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.